Skip to content

SPIRA™-A 3D and HCT/p DBM vs. Medtronic Divergent™-L/Perimeter™ and Recombinant BMP-2

SPIRA™-A 3D Printed Titanium Anterior Lumbar Interbody Fusion Device and HCT/p Demineralized Bone Matrix Versus Medtronic Divergent™-L/Perimeter™ PEEK Anterior Lumbar Interbody Fusion Device and Recombinant Bone Morphogenic Protein-2

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04566874
Enrollment
100
Registered
2020-09-28
Start date
2020-07-13
Completion date
2021-07-31
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease, Scoliosis, Spinal Stenosis, Spondylolisthesis

Keywords

lumbar spinal fusion

Brief summary

A prospective, randomized, controlled clinical evaluation utilizing the SPIRA™ ALIF 3-D printed titanium interbody device with DBM vs a Medtronic PEEK ALIF interbody device with BMP

Detailed description

This is a single blinded randomized 1:1, controlled, prospective clinical study to evaluate fusion status and patient reported outcomes in circumferential lumbar fusion between L2-S1 at a single level with posterior screw fixation (Camber Spine Orthros System) and anterior surgery consisting of one of the treatment groups: subjects treated with the SPIRA™-A Interbody Device and HCTP/p DBM or subjects treated with Medtronic Divergent-L or Perimeter™ PEEK ALIF Interbody Device and rhBMP-2 (6mg per level).

Interventions

DEVICEALIF

Anterior Lumbar Interbody Fusion

Sponsors

Camber Spine Technologies
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

subjects will be blinded prior to surgery. Following surgery, maintaining masking may not be feasible as subjects will have access to medical records and/or radiographs.

Intervention model description

single blind randomized 1:1

Eligibility

Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* skeletally mature adults * completed 6 month non-operative or conservative therapy * signed informed consent * back pain with radicular symptoms as evidenced by leg pain * Degenerative Disc Disease involving a single level between L2 and S1 * subject willing to participate in study and follow protocol * subject willing to comply with Post-op management program

Exclusion criteria

* systemic infection such as AIDS, HIV or Active hepatitis * autoimmune disease * significant metabolic disease that might compromise bone growth * history of malignancy * previous surgery for primary tumor, trauma or infection * subject requires 2 or more levels of fusion * previous spinal instrumentation or previous interbody fusion at involved level * spondylolisthesis of grade greater than/equal to 2

Design outcomes

Primary

MeasureTime frameDescription
Radiographic Fusion6 monthsAP/Lateral, Flexion, Extension and CT radiographs

Secondary

MeasureTime frameDescription
Oswestry Disability Indexup to and including 24 monthsImprovement in the ODI as measured by a minimum of a 15 point improvement
Back and Leg VASup to and including 24 monthsImprovement in the VAS as measured by a minimum of a 20 point improvement.
VR-12 Health Surveyup to and including 24 monthsImprovement in the VR-12 Health Survey as demonstrated by pre-op and post-op evaluation
PROMIS scoreup to and including 24 monthsChange in the PROMIS score

Countries

United States

Contacts

Primary ContactDonald W Guthner, BS
dguthner@cambermedtech.com646.460.2984
Backup ContactNoel Hetrick
nhetrick@cambermedtech.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026